GFR inhibitors Flashcards
GF inhibitor drugs
cetuximab
panitumumab
necitumumab
erlotinib
afatinib
osimertinib
bevacizumab
ziv-afilbercept
ramurcirumab
sorafenib
sunitnib
pazopanib
EGFR
overexpressed in solid tumors
VEGFR
angiogenic growth factor
Cetuximab: what it is, what kind of “isotype” it is, and its uses
chimeric monoclonal Ab against extracellular domain of EGFR: G1 isotype
combo w/irinotecan for metastatic colon cancer in “refractory setting” OR
monotherapy in patients irinotecan-refraectory OR
combo w/radiation against advanced head and neck cancer
Panitumumab: what it is, how it works, what kind of isotype it is, clinical
fully human monoclonal antibody direct against EGFR ; G2 isotype
refractory metastatic CRC in pts treated with other agents.
combins with FOLFOX chemo regimen in front line treatment of metastatic CRC
folfox regimen: oxaliplatin + 5 FU + folinic acid (leocovorin)
first line tx for metastatic NSCLC
erlotinib
used as maintenance therapy for metastatic NSCLC whose diz has not progressed after four cycles of platinum based chemo
erlotinib
diarrhea, aceniform rash, inihbits EGFR receptors
erlotinib
first line tx against CML
imatinib
fluid retention with periorbital edema
imatinib
inhibits BCR-ABL, c-KIT and PDGFR-β tyrosine kinases
dasatinib
indicated for CML as well ass 9;22+ ALL
dasatinib
fully human IgG1 monoclonal antibody direct against EGFRs
necitumumab
combined with gemcitabine and cisplatin chemo tx for squamous NSCLC
necitumumab
first line tx for metastatic NSCLC with EGFR mutations
afatinib
small molecule inhibitor of TKIs associated with EGFR, HER2, and HER4
afatinib
targets metastatic NSCLC w/EGFR T790M. what makes me distinct?
osimertinib: unique cardiotoxicity- QTc prolongation and cardiomyopathy
recombinant humanized monoclonal antibody that targets VEGF-A
bevacizumab
cetuximab vs panitumumab: molecule, isotype, immunonological effect
cetuximab: chimeric monoclonal antibody against EGFR
panitumumab: fully human monoclonal antibody EGFR
cetuximab: G1 isotype
panitumumab: G2 isotype
cetuximab- immunosystem stim
panti- no immune system stim
VEGF receptor inhibiting drugs
ziv-afilvercept ramucriumab sorafenib sunitinib pazopanib
used in pts deemed refractory to irinotecan
cetuximab
combined with radiation therapy in pts with locally advanced head and neck cancer
cetuximab
colorectal cancer
cetuximab and penitumumab
refractory metastatic colorectal cancer in pts treated with everything possible
panitumumab
FOLFOX combination therapy
frontline chemo regimen used is metastatic CRC
oxaliplatin + 5FU+folinic acid
approved for used with gemcitabine for tx of advanced pancreatic cancer
erlotinib
combined with f 5u, irinotecan, and ocaliplatin for metastatic colorectal cancer
bevacizumab
first line tx for metastatic colorectal cancer in combo with any IV fluoropyrimidine containing regimen
bevacizumab
used in the FOLFIRI regimen for patients with metastatic colorectal cancer that has progressed to oxiloplatin therapy
ziv-aflibercept
recombinant fusion protein made up of portions of extracellular domains of human VEGFR 1 and 2, fused to the Fc portion of the human IgG1 molecule
ziv-aflibercept
Receptor VEGFR A VEGF B and PIGF
ziv-aflibercept
